Enlivex Therapeutics (NASDAQ:ENLV) Hits New 1-Year Low – Should You Sell?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.4277 and last traded at $6.9210, with a volume of 816906 shares traded. The stock had previously closed at $7.2075.

Wall Street Analyst Weigh In

ENLV has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. HC Wainwright upped their price objective on Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Enlivex Therapeutics presently has an average rating of “Hold” and a consensus target price of $247.50.

Enlivex Therapeutics Stock Performance

The business has a 50-day moving average of $0.69 and a 200 day moving average of $0.88. The stock has a market cap of $1.66 billion, a PE ratio of -12.85 and a beta of 1.52.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Enlivex Therapeutics in the 4th quarter worth about $33,000. Invesco Ltd. acquired a new position in shares of Enlivex Therapeutics during the 4th quarter valued at about $43,000. XTX Topco Ltd increased its stake in shares of Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after acquiring an additional 19,132 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Enlivex Therapeutics by 244.1% during the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after acquiring an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the 3rd quarter worth about $57,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.